Global Leading Market Research Publisher QYResearch announces the release of its latest report ”Dissolvable Lacrimal Plugs – Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032″ . Based on current situation and impact historical analysis (2021-2025) and forecast calculations (2026-2032), this report provides a comprehensive analysis of the global Dissolvable Lacrimal Plugs market, including market size, share, demand, industry development status, and forecasts for the next few years.
For ophthalmologists, optometrists, and millions of patients suffering from the persistent discomfort of dry eye disease, the search for effective, convenient, and minimally invasive dry eye treatment options represents a significant healthcare priority. Traditional therapies—including artificial tears, prescription anti-inflammatory drops, and permanent punctal occlusion devices—impose burdens of frequent administration, systemic side effects, or irreversible anatomical alteration. Dissolvable lacrimal plugs address these fundamental limitations through innovative biodegradable eye implants that temporarily block tear drainage, preserve natural ocular moisture, and gradually dissolve without surgical removal. The global dissolvable lacrimal plugs market was valued at US$ 92.91 million in 2025 and is projected to reach US$ 143 million by 2032, expanding at a steady CAGR of 6.4% during the forecast period—a trajectory that reflects accelerating adoption of lacrimal occlusion therapy and ophthalmic medical devices across clinical and hospital settings worldwide .
【Get a free sample PDF of this report (Including Full TOC, List of Tables & Figures, Chart)】
https://www.qyresearch.com/reports/6089582/dissolvable-lacrimal-plugs
Market Analysis: Product Definition and Clinical Value Proposition
Dissolvable lacrimal plugs are specialized ophthalmic medical devices engineered for the temporary management of dry eye syndrome through punctal occlusion devices technology. Fabricated from biocompatible, biodegradable eye implants materials, these devices are inserted into the tear ducts (puncta) to reduce aqueous tear drainage, thereby preserving natural moisture on the ocular surface. Unlike permanent punctal plugs requiring surgical removal, dissolvable lacrimal plugs gradually degrade and are safely absorbed by the body, eliminating secondary procedures and reducing patient treatment burden. These dry eye treatment devices are particularly suitable for short-term or transitional therapy, providing effective symptomatic relief while enhancing ocular comfort .
In the global ophthalmic treatment landscape, dissolvable lacrimal plugs have emerged as an innovative, minimally invasive dry eye treatment solution. Their unique biodegradable properties and high patient compliance are driving sustained market demand worldwide, with North America standing out as the leading consumer region. Dry eye disease has become a significant global health concern, affecting quality of life for millions. Lifestyle changes, environmental factors, and population aging have contributed to rising disease incidence. Traditional treatments often require indefinite use of artificial tears or chronic medication regimens. In contrast, dissolvable lacrimal plugs offer a more convenient and comfortable punctal occlusion devices alternative. The primary advantage lies in biodegradability—unlike permanent ophthalmic medical devices, these biodegradable eye implants gradually dissolve within the eye, eliminating surgical removal and significantly reducing patient burden. Additionally, their minimally invasive nature ensures reduced procedural discomfort, enhancing the overall therapeutic experience.
Market Segmentation and Competitive Landscape
The Dissolvable Lacrimal Plugs market is segmented as below:
By Manufacturer:
Ocular Therapeutix (DEXTENZA), Corza Medical (EagleVision, UltraPlug), FCI Ophthalmics, Innovia Medical (Lacrimedics), Oasis Medical, Lacrivera, MDCO (Medennium)
Segment by Type:
Lacrimal Plugs Dissolve Within 30 Days | Lacrimal Plugs Dissolve Above 30 Days
Segment by Application:
Hospitals | Clinics
Regional Market Dynamics and Clinical Adoption Patterns
North America has emerged as the largest consumer market for dissolvable lacrimal plugs globally. According to market analysis, North America accounted for approximately 46% of the global market share in 2024. This dominance is attributable to the region’s highly developed healthcare infrastructure, advanced ophthalmic technologies, and strong emphasis on eye health. The United States, with high dry eye disease prevalence and receptive patient populations, provides favorable conditions for dissolvable lacrimal plugs adoption.
In terms of application setting, clinics have become the primary market for dissolvable lacrimal plugs. In 2024, clinics accounted for approximately 63% of the global market. This trend reflects patient demand for convenient, accessible dry eye treatment. Clinics typically offer flexible scheduling and affordable fees, making them attractive for patients seeking punctal occlusion devices therapy. Clinic-based ophthalmologists have accumulated extensive experience in diagnosing and managing dry eye disease, providing professional ophthalmic medical devices services. Although hospitals maintain market presence, their application of dissolvable lacrimal plugs is relatively limited. Hospitals often manage complex ophthalmic conditions with more involved treatment processes. Patients in hospital settings may gravitate toward permanent dry eye treatment solutions, positioning hospitals in a supportive role for dissolvable lacrimal plugs application.
Industry Trends: Biodegradable Material Innovation and Patient Compliance
The dissolvable lacrimal plugs market is propelled by continuous innovation in biodegradable eye implants materials and device design. Contemporary punctal occlusion devices incorporate advanced polymer formulations providing predictable dissolution kinetics—spanning options that dissolve within 30 days for short-term diagnostic or post-surgical applications, and extended-duration ophthalmic medical devices dissolving over longer periods for sustained dry eye treatment. Material science advancements enable dissolvable lacrimal plugs with enhanced biocompatibility, reduced inflammatory response, and consistent lacrimal occlusion therapy performance.
Patient compliance advantages represent an equally powerful market catalyst. Unlike daily artificial tear regimens or chronic prescription medications, dissolvable lacrimal plugs provide continuous dry eye treatment without ongoing patient adherence requirements. This “set and forget” therapeutic approach resonates strongly with busy patients and those experiencing medication fatigue.
Strategic Outlook
As dry eye disease prevalence escalates globally, patient expectations for convenient dry eye treatment intensify, and punctal occlusion devices technology advances, dissolvable lacrimal plugs capable of delivering reliable lacrimal occlusion therapy, predictable biodegradable eye implants performance, and patient-friendly ophthalmic medical devices experience will sustain steady growth momentum. The market’s 6.4% CAGR reflects strong demand across hospital and clinic settings, amplified by North American market leadership and expanding global awareness of dissolvable lacrimal plugs benefits. For patients, this means expanded treatment options and improved quality of life; for healthcare institutions, this represents an opportunity to enhance service quality while meeting evolving patient needs for convenient, effective dry eye treatment solutions through 2032.
Contact Us:
If you have any queries regarding this report or if you would like further information, please contact us:
QY Research Inc.
Add: 17890 Castleton Street Suite 369 City of Industry CA 91748 United States
EN: https://www.qyresearch.com
E-mail: global@qyresearch.com
Tel: 001-626-842-1666(US)
JP: https://www.qyresearch.co.jp
